Aesthetic Plastic Surgery

, Volume 30, Issue 4, pp 474–478 | Cite as

Injection of Phosphatidylcholine in Fat Tissue: Experimental Study of Local Action in Rabbits

  • Patrícia Guedes Rittes
  • José Carlos Rittes
  • Maria Fernanda Carriel Amary



Subcutaneous phosphatidylcholine to cause local lipolysis has been performed effectively and safely in the nonsurgical treatment of periorbital fat pads and also in the treatment of localized fat deposits in the abdomen, neck, arms and thighs. However, the studies do not explain the mechanism through which injectable phosphatidylcholine causes localized fat reduction. This study aimed to compare the local action of a phosphatidylcholine formulation with that of a physiologic saline solution in a histologic study investigating the fat tissue of rabbits.


Using a randomized, blind approach, 10 rabbits were injected with an experimental assay of phosphatidylcholine (the biologic model), and another 10 rabbits were injected with physiologic saline. A histologic study was conducted, and the Mann–Whitney test was applied.


A marked difference was observed between the two groups with respect to necrosis, inflammatory exudation, and fibrosis.


Necrosis of the fat cells in all the phosphatidylcholine-injected animals was observed. Further studies should be performed to clarify and determine the mechanisms of action.


Experimental study of fat tissue Phosphatidylcholine injection 



The authors are grateful to Andreia Bonizzia Zanqui, biologist, and Fernanda Vasques Daud, veterinarian, for technical assistance.


  1. 1.
    Ablon G, Rotunda AM: Treatment of lower eyelid fat pads using phosphatidylcholine: clinical trial and review. Dermatol Surg 30:422–427, 2004PubMedCrossRefGoogle Scholar
  2. 2.
    Fiume Z: Final report on the safety assessment of lecithin and hydrogenated lecithin. Int J Toxicol 20(Suppl 1):21–45, 2001PubMedGoogle Scholar
  3. 3.
    Galli C, Tremoli E, Giani E, Maderna P, Gianfranceschi G, Sirtori CR: Oral polyunsaturated phosphatidylcholine reduces platelet lipid and cholesterol contents in healthy volunteers. Lipids 20:561–566, 1985PubMedGoogle Scholar
  4. 4.
    Kirsten R, Heintz B, Nelson K, Oremek G: Reduction of hyperlipidemia with 3-sn-polyenyl-phosphatidylcholine in dialysis patients. Int J Clin Pharmacol Ther Toxicol 27:129–134, 1989PubMedGoogle Scholar
  5. 5.
    Rittes PG: The use of phosphatidylcholine for correction of localized fat deposits. Aesth Plast Surg 27:315–318, 2003CrossRefGoogle Scholar
  6. 6.
    Rittes PG: The use of phosphatidylcholine for correction of lower lid bulging due to prominent fat pads. Dermatol Surg 27:391–392, 2001PubMedCrossRefGoogle Scholar
  7. 7.
    Rose PT, Morgan M: Histological changes associated with mesotherapy for fat dissolution. J Cosmet Laser Ther 7:17–19, 2005PubMedCrossRefGoogle Scholar
  8. 8.
    Warembourg H, Jaillard J: Clinical trial of Lipostabil in the treatment of diabetic angiopathy. Lille Med 13(Suppl):31, 1968Google Scholar
  9. 9.
    Wattel F, Scherpereel P, Sezille G, Fruchart JC: Use of polyunsaturated phospholipids in the treatment of fat embolism. Lille Med 19(8 Suppl 3):870–874, 1974PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  • Patrícia Guedes Rittes
    • 1
  • José Carlos Rittes
    • 1
  • Maria Fernanda Carriel Amary
    • 1
  1. 1.Santa Casa School of MedicineSão PauloBrazil

Personalised recommendations